U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C25H23ClN4O4
Molecular Weight 478.928
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PAZINACLONE

SMILES

ClC1=NC2=NC(=CC=C2C=C1)N3C(CC(=O)N4CCC5(CC4)OCCO5)C6=CC=CC=C6C3=O

InChI

InChIKey=DPGKFACWOCLTCA-UHFFFAOYSA-N
InChI=1S/C25H23ClN4O4/c26-20-7-5-16-6-8-21(28-23(16)27-20)30-19(17-3-1-2-4-18(17)24(30)32)15-22(31)29-11-9-25(10-12-29)33-13-14-34-25/h1-8,19H,9-15H2

HIDE SMILES / InChI

Molecular Formula C25H23ClN4O4
Molecular Weight 478.928
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description

Isoindoline pazinaclone (also known as DN-2327), a partial agonist at GABAA benzodiazepine receptors, produced anxiolytic, taming and anti-convulsive effects. This neuropsychiatric drug was involved in phase II clinical trial for patients with generalized anxiety disorder. However, this study was discontinued.

Originator

Approval Year

PubMed

Sample Use Guides

In Vivo Use Guide
pazinaclone 8 mg/day bid for 4 weeks in a placebo-controlled study involving 126 patients
Route of Administration: Oral
Substance Class Chemical
Record UNII
MHK03047IJ
Record Status Validated (UNII)
Record Version